For the treatment of NLRP3-mediated diseases, neutralizing antibodies against IL-1β and IL-18 are usually used, the development of drugs that inhibit pro-inflammatory factors such as IL-1β targeted inhibitors has also become a research hotspot in the adjuvant treatment of neurological diseases, but the effect is not ideal. This evidence concerns the gene NLRP3 and glycogen storage disease VI.